Transformation beyond reform
A changing life sciences & health care industry
What lies ahead for global life sciences companies as they focus on the practicalities of dealing with the provisions and impacts of U.S. health care reform?
Deloitte joined senior life science executives, industry leaders, payors, and financers from around the world at the Financial Times U.S. Healthcare and Life Sciences Conference to debate, discuss, and respond to today's critical industry issues.
- New Financing and Business Models for Life Sciences Innovation by Reynold W. (Pete) Mooney, Global LSHC Industry Leader, DTTL
- What is driving life sciences transformation? by Terry Hisey, vice chairman and Life Sciences leader for Deloitte LLP in the United States
|Health reform and life sciences: Threat, opportunity or both?
New survey of 295 senior life sciences execs shows enhancing innovation, reducing costs, widening market access, and changing sales models are seen as major impacts on the life sciences industry from health care reforms around the world.
|Transformation beyond reform: The impact of health care reform on the life sciences industry
Listen to the podcast, featuring Deloitte life science and health care industry leaders discussing Financial Times U.S. Healthcare and Life Sciences Conference topics.
|Big pharma: Business model choices for the new market
The pharmaceutical industry faces a critical need for change. Explore ideas as to how pharmaceutical companies can re-orient their business model to deliver value in the new life sciences market.
|2013 Global life sciences sector outlook
New report examines the current state of the global life sciences industry, explores top issues, reviews activity in a number of geographic markets, and suggests considerations for companies as they seek to grow revenue and market share in 2013 and beyond.
|Measuring the return on innovation: Is R&D earning its investment?
Third edition includes analysis of the top global pharmaceutical companies and compares results over the three year survey. The report also conducts an analysis into value measurement at the "whole R&D business" level using Internal Rate of Return (IRR).
|Building on the BRICs: Redraw the global map of opportunity and competition
As growth slows in the BRIC countries, multinationals from developed nations may find seven new emerging markets to hold enticing opportunities.
|Life Sciences: Accounting and Financial Reporting Update
Publication highlights specialized accounting and reporting considerations applicable to companies in this life sciences industry.
|2013 Deloitte survey of U.S. physicians: Perspectives about health care reform and the future of the medical profession
U.S. physicians are concerned future of medical profession may be in jeopardy and performance of the U.S. health care system is suboptimal, but the Affordable Care Act will address this.
|Global HCP transparency study
Deloitte has executed a Global Health Care Professional (HCP) Transparency Study to provide insights into countries' current and anticipated regulatory requirements for tracking payments and transfers of value that life sciences companies make to health care professionals and organizations (HCP/O).
|Health care's 5 Cs
The story line about health care in 2013 will center on five themes: Clarity, Costs, Compliance, Consolidation, and Consumers.